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Objective: Analyze the influence between the components of metabolic syndrome and the 
independent risk for cardiovascular disease (CVD) in the elderly.
Methods: A descriptive cross-sectional study was carried out with 205 older adults from 
a primary healthcare unit of the Federal District, Brazil. The cardiovascular risk was 
determined by the Framingham Risk Score (FRS). The National Cholesterol Evaluation 
Program for Adult Treatment Panel III 2001 (NCEP-ATP III) criteria were considered to 
analyze metabolic syndrome (MS) diagnoses.
Results: There was a strong association between MS and high cardiovascular risk (OR = 8.86). 
The univariate analysis main findings revealed that male gender, diabetes, smoking habit, 
systolic blood pressure, HDL level, high blood glucose, glycated hemoglobin, and LDL level 
were associated with high cardiovascular risk. FRS increases significantly with the presence of 
four or more MS components (by 30%, if 4 components are present, and by 40%, if 5 
components) when compared with the presence of three or fewer components (P <0.001). 
A logistic regression analysis of high-risk predictors was described to reduce the effects of 
confounding and bias factors.
Conclusion: The identification of MS associated with high FRS values represents 
a cascading of adverse effects on the population’s aging process.
Keywords: aged, metabolic syndrome, cardiovascular system, aging population
Introduction
The impact of the aging population is noticeable in several fields of society, 
especially in the healthcare area. The continuing increase in the aging population’s 
longevity rates has become a challenge for public health care, primarily due to an 
increase in the number of chronic non-communicable diseases (NCDs) and the 
complications of multifactorial etiology.1 Brazil is among the six countries with the 
largest aging population in the world. This population is expected to exceed 
26.2 million individuals, equivalent to approximately 12.4% of the total Brazilian 
population, by 2020.2 According to the Brazilian Society of Geriatrics and 
Gerontology, in the year 2032, there will be roughly 32.5 million Brazilians older 
adults.3
The development of poor habits in the aging population exponentially increases 
the risk of metabolic syndrome (MS), which, in turn, may trigger or exacerbate 
NCDs and cardiovascular disorders.4 The Brazilian Guideline on the Diagnosis and 
Treatment of Metabolic Syndrome defines the disease as a set of cardiovascular and 
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metabolic factors.5 In the international scenario, it is esti-
mated that 25% of the population has components indica-
tive of MS diagnosis,6 which may lead to 7% of deaths. 
Furthermore, data suggest that 17% of the cardiovascular 
system deaths occur due to MS.7 Evidence in the literature 
indicates that the MS prevalence increases with age, repre-
senting an increase of 2.5 times that of cardiovascular 
diseases (CVD) risk.8 In this respect, the literature has 
a large number of studies attesting the relationship 
between MS and its prevalence in older adults.8–11 
A specific study revealed that by 2012 more than a third 
of the US adult population met the definition and criteria 
for MS.12
Cardiovascular risk classification is a follow-up strat-
egy and indicator of the quality of treatment implemented 
in individuals belonging to a high-risk group. The 
Framingham Risk Score (FRS) is one of the main cardio-
vascular risk stratification methods recommended by the 
Brazilian Ministry of Health. In the literature, the results 
of its use have been of utmost importance in CVD primary 
prevention.13,14
Therefore, the present study aims to analyze the influ-
ence between the MS components and the independent 
risk for CVD in older adults. The initial hypothesis was 
that older adults with a higher number of MS components 
have a higher risk of developing CVD.
Method
Subjects
The participants ‘designation flowchart in the study is 
displayed in Figure 1. A descriptive cross-sectional 
study with a quantitative approach carried out in 
a primary healthcare unit (UBS, per its Portuguese) of 
the Federal District (FD), Brazil. The study population 
was composed of older adults who met the following 
inclusion criteria: being 60 years or older (considered an 
older adult in Brazil), receiving monitoring in the UBS, 
and a sound mind. The study sample was of 205 parti-
cipants, with a 5% margin of error and a 95% confi-
dence level.
Individuals with a previous cardiac event, informed at 
the time of the interview, were excluded from this study. 
The following exclusion criteria were considered: having 
a score ≤9 points on the Mini-Mental Health Examination 
(MMSE) test and having a pacemaker or metallic prosthe-
sis. The Secretariat of Health of the Federal District 
research ethics committee approved this study (protocol 
1.355.211/2017). All information was collected after 
a written consent document was obtained from all partici-
pants. It followed the principles of the National Research 
Council according to legislation in force in Brazil provided 
for in the Resolution n° 46 (2012) and according with the 
Declaration of Helsinki.
Figure 1 The participants’ designation flowchart in the study. Brasília, 2019.
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Study Presentation
The data collection stages occurred after signing an 
informed consent form (ICF), from February to 
June 2019. Each item was properly clarified, and ethical 
aspects established within the national territory were 
respected. The responsible researchers were readily avail-
able for possible events.
Collection
The first step was a blood sample collection after a fasting 
period. Approximately 15 mL of venous blood from the 
cubital vein region were collected, followed by food pro-
vision for diabetic patients. The second step was the appli-
cation of a structured data collection survey for evaluation 
of patients’ demographic and socioeconomic profiles, con-
stituted by closed questions concerning gender, age, edu-
cation level, retirement, income, life habits (smoking), 
clinical conditions (hypertension or diabetes mellitus diag-
nosis), and medication use (type and administration route). 
This stage’s objective was to characterize the population 
involved; researchers also addressed questions and clari-
fied possible doubts. This research was conducted in the 
FD region with the lowest education and human develop-
ment index rates. The population studied is also part of the 
FD densest population mass and is close to the largest 
slum (favela).
Cardiovascular Data and Anthropometric 
Measurements
Blood pressure (BP) was measured following the criteria 
established by the Brazilian Guideline on Hypertension.15 
Regarding the anthropometric measurements evaluation, 
weight and height were determined using a measuring 
tape and scale (SANNY brand), and the body mass index 
(BMI) was calculated implementing the weight/height2 
formula. Previously trained evaluators obtained the mea-
surements with the application of Lohman’s techniques 
(1988). The following BMI reference values were consid-
ered: normal (22.0 kg/m2 to 27.0 kg/m2) and overweight 
(>27 kg/m2). Body composition was evaluated employing 
a dual-energy X-ray absorptiometry examination (DXA, 
model 8548 BX1L, Lunar DPX type, software Encore 
2005, GE Healthcare Europe GmbH Freiburg, 
Germany).16
The Framingham Risk Score (FRS) was used to deter-
mine cardiovascular risk, where each variable presented 
value ranges with specific positive or negative scores. The 
total score was calculated by applying the following vari-
ables: age, gender, smoking, diabetes mellitus (DM), 
HDL, total cholesterol (TC), systolic blood pressure 
(SBP), and diastolic blood pressure (DBP). The resulting 
score corresponds to a probability percentage of coronary 
artery disease (CAD) occurrence in the next ten years. The 
use of FRS to determine cardiovascular risk is presented 
by Simão et al5 as an economically viable and efficient 
strategy for tracking patients at high risk and a more care-
ful managing of the risk factors.
The FRS classification is thus determined: low, if risk 
<10% in 10 years; intermediate, if between 10–20%; and 
high, if >20%. Hence, patients are considered at high 
cardiovascular risk when FRS >20%.
Metabolic Syndrome
The Brazilian Society of Cardiology criteria were used to 
analyze the MS diagnoses that followed the Brazilian 
Guideline on the Diagnosis and Treatment of Metabolic 
Syndrome. This Guideline does not require insulin measure-
ment and adopts the National Cholesterol Evaluation 
Program for Adult Treatment Panel III 2001 (NCEP-ATP 
III) as a clinical criterion. The following components were 
evaluated: waist circumference (WC) >88 cm for women and 
>102 cm for men; BP ≥130x85mmHg or the use of an 
antihypertensive; fasting glucose ≥110mg/dL or a DM type 
2 diagnosis; triglyceride (TG) ≥150mg/dL; and HDL-c 
<40mg/dL for men and <50mg/dL for women. The presence 
of at least three components is required for an MS diagnose.17
Statistical Analysis
A database was created using the Statistical Package for 
the Social Sciences 20 (SPSS). Foremost, relative and 
absolute frequencies, dispersion measures, mean, and stan-
dard deviation were calculated. The Kolmogorov–Smirnov 
test was applied to analyze the variables’ normality. The 
t-test and the ANOVA test were employed to compare 
differences among groups. The Spearman correlation coef-
ficient was performed for the correlations analysis of 
numerical variables. P-values of <0.05 were considered 
statistically significant.
Regression analysis was employed to reduce the effects 
of confounding and bias factors. To determine the logistic 
regression mathematical model, the criteria of Hair et al 
(2005), which includes 20 cases for each predictor variable 
and a minimum of 5 cases, was adopted.18
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Results
Two-hundred five older adults participated in the study. 
Most were women, aged between 60 and 64, with one to 
four years of education, not retired, and with a monthly 
income of less than or equal to one minimum wage. Some 
variables, such as educational level, retirement, and 
income, collected did not present a significant association 
with the presence of high cardiovascular risk.
For the selection of possible candidate variables to pre-
dict high cardiovascular risk according to the FRS classifi-
cation criteria, a univariate association analysis was first 
performed, as described in Table 1. It was noted that the 
variables males (p=0.001); Metabolic Syndrome (MS) pre-
sence (p<0.001); Diabetes Mellitus (DM) presence 
(p<0.001); smoking (p=0.027); altered systolic blood pres-
sure - SBP (p<0.001); altered diastolic blood pressure -DBP 
(p=0.008); low HDL levels (p<0.001); high blood glucose 
(p<0.001); elevated glycated hemoglobin (p<0.001); high 
LDL levels (p=0.007); and CVD risk (p<0.001) were asso-
ciated as risk factors for cardiovascular risk (OR>1.0).
As the MS presence was strongly associated with high 
cardiovascular risk (OR = 8.86), it was decided to inves-
tigate further this connection. The median FRS difference 
was evaluated under different combinations of MS com-
ponents. FRS had a significant median increase of 30% 
and 40% in the presence of 4 and 5 included components, 
respectfully, when compared to the presence of 1 to 3 
components (P<0.001; Figure 2). Thus, FRS increases 
significantly in the presence of at least four MS compo-
nents. Nonetheless, these FRS median did not differ 
between low numbers (1, 2, or 3) or high numbers (4 
or 5) of components.
The other variables that were statistically associated 
with the high FRS value were eligible for the logistic 
regression model. The results showed that the model com-
posed of these variables was significant (p<0.01) for the 
explanation of the variable criterion “Cardiovascular risk,” 
measured in terms of the proportion of the high FRS 
category presence. The model’s adjustment was expres-
sive, and adequately classified 87.1% of the individuals 
present in the sample. Table 2 presents the results of the 
logistic return analysis, in which return coefficients are: 
not standardized (B), meaning level (sig.), odds ratios for 
the predictors (Exp(B)), and the intercept (constant). Thus, 
predictors for high cardiovascular risk are altered SBP, 
male gender, DM presence, smoking habit, and alteration 
in HDL and LDL biochemical components.
Finally, for a better comprehension of the body and 
biochemical composition in the different FRS categories, 
Table 3 was constructed. In the comparison among risk 
groups, higher mean values were found in the high-risk 
group, such as triglycerides and BMI, compared with the 
moderate and low-risk group (P =0.003 and P = 0.036, 
respectively). Likewise, when comparing blood glucose, 
glycated hemoglobin, waist circumference (WS), SBP, 
DBP, and HDL, higher mean values were found in the 
high-risk group when compared with the moderate and 
low-risk group which had similar mean values (Table 3).
Discussion
This study analyzed the influence between the metabolic 
syndrome (MS) components and the independent risk for 
cardiovascular disease (CVD) in older adults confirming 
the initial hypothesis that individuals with a higher number 
of MS components have a higher risk for developing 
CVD. Furthermore, a quarter of the older adults with MS 
had a high risk of developing CVD compared to those 
without MS. Though it is important to note that old adults 
with diabetes mellitus (DM), increased systolic blood pres-
sure (SBP), smoking habit, and a high LDL level demon-
strated a high cardiovascular risk regardless of having MS.
MS seems to increase cardiovascular risk while also 
carrying other commodities. Mansourian et al19 claim that 
MS individuals have twice as much risk compared to the 
general population. MS represents a condition that 
deserves attention due to the complexity of components 
and risk factors.20 For a better comprehension of its influ-
ence, analyzing the current diagnoses are essential. Many 
studies investigate specific clinical conditions, such as the 
impairment of the cardiovascular system, yet clinical con-
ditions depend on the prevalence of the number of MS 
components and the associated risk factors.21,22
The statistics on the present study sample indicate that 
increased cardiovascular risk is closely associated with 
older adults who have more MS components. The pre-
sence of 4 MS components increases cardiovascular risk 
by 30%, while 5 components increase the risk by 40%, 
compared to the elderly with 3 or fewer components. 
A study found that MS individuals had an increased pre-
valence of coronary heart disease and stroke, illustrating 
the link between health conditions.23
The biochemical profile showed significant metabolic 
alterations in old adults who met the high cardiovascular 
risk criteria. The prevalence of changes in lipid, glycemic, 
and BMI profiles causes several associated systemic 
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Table 1 High-Risk Category to the Framingham Risk Score (FRS) in Older Adults According to Demographic, Anthropometric, 
Biochemical, Clinical, and Socioeconomic Variables. Brasilia, 2020
High ardiovascular Risk (FRS)
Yes No
N % N % P-value OR CI (OR) 95%
Gender Female 23 57.50 133 80.60 0.002* 0.33 0.16–0.68
Male 17 42.50 32 19.40
Age (in years) > 65 27 67.50 92 55.80 0.177 1.65 0.79–3.42
60 to 64 13 32.50 73 44.20
MS Yes 37 92.50 96 58.20 <0.001* 8.86 2.63–29.92
No 3 7.50 69 41.80
Hypertension Yes 34 85.00 124 75.20 0.183 1.87 0.73–4.78
No 6 15.00 41 24.80
DM Yes 34 85.00 82 49.70 <0.001* 5.74 2.29–14.39
No 6 15.00 83 50.30
Smoking Yes 7 17.50 10 6.10 0.027* 3.29 1.17–9.27
No 33 82.50 155 93.90
Alcohol Yes 4 10.00 7 4.20 0.23 2.5 0.70–9.03
No 36 90.00 158 95.80
Physical activity Yes 26 65.00 116 70.30 0.511 0.78 0.38–1.63
No 14 35.00 49 29.70
SBP Yes 23 63.90 34 23.80 <0.001* 5.67 2.60–12.39
No 13 36.10 109 76.20
DBP Yes 18 50.00 38 27.10 0.008* 2.68 1.27–5.69
No 18 50.00 102 72.90
Triglycerides > 151 mg/dL 18 45.00 66 40.00 0.565 1.23 0.61–2.46
Until 150 mg/dL 22 55.00 99 60.00
HDL Until 39 mg/dL 18 46.20 22 13.30 <0.001* 5.57 2.57–12.07
> 40 mg/dL 21 53.80 143 86.70
Glucose > 100 mg/dL 31 77.50 76 46.10 <0.001* 4.03 1.81–9.00
Until 99 mg/dL 9 22.50 89 53.90
GH > 5.8% 32 84.20 78 50.60 <0.001* 5.2 2.06–13.14
Until 5.7% 6 15.80 76 49.40
Total cholesterol > 191 mg/dL 25 64.10 77 50.00 0.115 1.79 0.86–3.69
Until 190 mg/dL 14 35.90 77 50.00
LDL > 111 mg/dL 27 73.00 73 48.70 0.007* 2.85 1.29–6.29
Until 110 mg/dL 10 27.00 77 51.30
PBF > 30% 30 88.2% 120 95.2% 0.222 0.38 0.10–1.41
Until 30% 4 11.8% 6 4.8%
BMI > 28 kg/m2 19 55.90 60 47.60 0.392 1.39 0.65–2.99
22.0 kg/m2 to 27.0 kg/ 
m2
15 44.10 66 52.40
(Continued)
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diseases. Factors related to abdominal fat accumulation 
and increased waist circumference (WC) are associated 
with the lipid process, which, when increased releases 
inflammatory mediators into the bloodstream.24 Lack of 
glycemic control activates hepatic mechanisms that rise 
lipoprotein synthesis, increasing LDL levels, and reducing 
HDL levels. These factors are strongly associated with 
cardiovascular risk,23,25 which supports the metabolic 
results of this study. Results similar to these were found 
in our previous study, revealing that a more meticulous 
analysis of biochemical components allows a better com-
prehension of the MS progression status in the elderly 
population.26
Factors involving lipids are present in the pathologi-
cal process of obesity. Although these lipid profile factors 
do not affirm the obesity diagnosis, they alert to patterns 
Table 1 (Continued).   
High ardiovascular Risk (FRS)
Yes No
N % N % P-value OR CI (OR) 95%
Cardiovascular risk in 10 yeas High 40 100.00 1 0.60 <0.001* NA NA
Intermediate and low 0 0.00 164 99.40
WC >88 cm for women 
and >102 cm for men
28 80.00 98 78.40 0.841 1.1 0.43–2.80
Until 88 cm for 
women and 102 cm 
for men
7 20.00 27 21.60
Note: *P<0.05. 
Abbreviations: BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; DBP, diastolic blood pressure; FRS, Framingham Risk Score; GH, glycated hemoglobin; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; MS, metabolic syndrome; NA, not applicable; OR, odds ration; PBF, percentage of body fat; SBP, systolic blood 
pressure; WC, waist circumference.
Figure 2 Effect of Metabolic Syndrome (MS) components on Framingham Risk Score (FRS) values. Brasilia, 2019 (n=205). Kruskal–Wallis´: p<0.001; Bonferroni correction 
test comparison of the FRS median of four or five components with one, two, or three are statistically significant (P<0.050). The “x” mark on the boxplot denotes the data 
mean.
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that expose the risk of obesity development. These pat-
terns reaffirm inflammatory conditions that, when asso-
ciated with the increased life expectancy, have a high 
potential for cognitive impairment and decreased quality 
of life.27
In our previous study, a correlation between the inflam-
matory process and the anthropometric state was 
evidenced.28 This inflammatory process begins with the 
lipoproteins agglomeration in the vessel walls and is 
related to adipokines’ function as proinflammatory 
mediators.24,29
Our results reveal an association between decreased 
HDL levels and high cardiovascular risk. This result 
confirms previous studies that connected low HDL 
levels to alterations that represent cardiovascular com-
plications, presenting HDL levels as an independent 
predictive variable for MS.30 It is important to remem-
ber that cholesterol is an essential molecule for the 
proper functioning of homeostasis. The distinct types 
of cholesterol perform specific functions within the 
body, with HDL molecule being responsible for elimi-
nating the cholesterol accumulation in the walls of the 
Table 3 Framingham Risk Score of Older Adults According to Biochemical and Nutritional Variables. Brasilia, 2018 (n=205)
Framingham Risk Score
Low (n=62) Moderate (n=103) High (n=40)
M SD M SD M SD P-value
Triglycerides (mg/dL) 133.77 a 56.05 155.19 a,b 70.60 183.58b 99.39 0.003*
HDL (mg/dL) 51.70 a 11.20 48.65 a 8.09 41.25 b 10.41 <0.001*
Glucose (mg/dL) 110.97 a 43.58 110.45 a 38.46 153.96 b 70.91 <0.001*
Glycated hemoglobin (%) 6.13 a 1.11 6.06 a 1.18 7.39 b 2.03 <0.001*
Total cholesterol (mg/dL) 189.97 50.10 194.49 39.90 207.84 47.11 0.143
LDL (mg/dL) 111.26 47.52 114.91 34.84 126.03 46.11 0.221
PBF (%) 45.0 5.6 44.2 7.4 43.8 8.9 0.722
BMI (kg/m2) 29.01 a 4.69 29.63 a,b 4.73 31.60 b 5.15 0.036*
WC 98.70 a 9.58 96.92 a 12.03 105.29 b 12.42 0.002*
SBP 135.45 a 20.12 132.88 a 16.60 150.28 b 18.42 <0.001*
DBP 81.23 a 14.85 80.16 a 11.92 88.00 b 13.19 0.020*
Notes: *P<0.050; ANOVA test; Different letters denote means statistical difference (Tukey´s test, P<0.005). 
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; M, mean; PBF, percentage of body fat; SD, 
standard deviation; SBP, systolic blood pressure; WC, waist circumference.
Table 2 Logistic Regression of Predictors of High Cardiovascular Risk. Brasilia, 2020 (n=205)
Variables in the Equation
B S.E. Wald df Sig. Exp(B) 95% C.I. for EXP(B)
Bottom Upper
1st Stage Gender (1) −1.819 0.646 7.931 1 0.005 0.162 0.046 0.575
DM (1) 2.217 0.842 6.935 1 0.008 9.179 1.763 47.793
Smoking (1) 1.912 0.825 5.376 1 0.020 6.769 1.344 34.083
SBP (1) 2.717 0.751 13.085 1 0.000 15.140 3.473 65.998
DBP (1) 0.226 0.739 0.093 1 0.760 1.253 0.294 5.335
HDL (1) 1.770 0.669 6.991 1 0.008 5.870 1.581 21.799
Glucose (1) −0.059 0.747 0.006 1 0.938 0.943 0.218 4.076
GH (1) 1.347 0.726 3.441 1 0.064 3.847 0.927 15.975
LDL(1) 2.432 0.693 12.319 1 0.000 11.377 2.926 44.232
Constant −6.129 1.392 19.375 1 0.000 0.002
Notes: a. Variable(s) inserted in stage 1: Gender, DM, Smoking, SBP, DBP, HDL, Glucose, GH, LDL. B=values for the logistic regression equation for predicting the dependent 
variable from the independent variable; df=degrees of freedom for the model; Sig.=two-tailed P-value for Wald chi-square value; Exp(B)=odds ratios for the predictors. 
Abbreviations: DM, diabetes mellitus; DBP, diastolic blood pressure; GH, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PBF, 
percentage of body fat; SBP, systolic blood pressure; CI, confidence interval.
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vessels and arteries, thus preventing complications. 
Hence, when HDL levels are below optimum, the higher 
risk for CVD development.
Table 2 also presents the correlation between LDL 
levels and high cardiovascular risk. LDL molecule is 
responsible for transporting the cholesterol deposited in 
the liver to the arteries, and when accumulated may form 
an obstruction. Increases in LDL levels may be associated 
with behavioral factors such as inadequate nutrition, use of 
specific medications, and intrinsic factors, eg, overweight 
and genetics. The LDL role associated with cardiovascular 
impairment may trigger CVD development, and this asso-
ciation may be enhanced by factors such as a smoking 
habit, DM, and hypertension.23,25,31
DM was identified in this study as predictive of high 
cardiovascular risk and is one of the factors involved in the 
MS process. Some studies cite MS as a predictor for the DM 
diagnosis.32–34 Despite this association, the literature has 
also described DM as an insufficient predictor of cardiovas-
cular impairments.35,36 Yet, many other studies associate 
DM with the appearance of complications in the cardiovas-
cular system.37–39 Therefore, DM is a potential predictor, 
knowing that it may cause impairment of the vascular sys-
tem walls, in addition to carrying other clinical factors such 
as obesity, physical inactivity, and dyslipidemia.40,41
The overall diabetic population is denoted at high 
cardiovascular risk. Relevant to underline that these con-
ditions have treatment and control, and it is possible to 
stabilize them, as long as there are adequate monitoring 
and access to treatment.42 These responsibilities fall on 
primary health care for it has higher power for direct 
monitoring.14 Studies carried out in line with the 
Cardiovascular Health Study (CHS) corroborate data 
from past and current decades, showing that CVD and 
MS have a favorable prognosis with the early recognition 
of the risk and adherence to the treatment plan.43
Regarding blood pressure, this study presents similar 
results to those found in literature, demonstrating 
a correlation between the set of MS components and the 
CVD risk. A review study conducted in Japan showed MS 
as a potential predictor of mortality from CVD associated 
complications.32 In the USA, a cohort study revealed that 
MS patients are 30% more likely to develop CVD.44 When 
studying CVD according to the MS risk factors, an Iranian 
study45 revealed that the highest number of MS compo-
nents is associated with the highest risk of cardiovascular 
complications. This association of component numbers 
may be related to the systemic repercussion of each of 
the MS risk factors and components. These include insulin 
resistance, which, in turn, is related to the increase in 
circulating glucose and DM diagnosis. Other complica-
tions related to this health condition, such as vasoconstric-
tion and sodium retention, generate an intimate connection 
with blood pressure variations, especially the systolic.45
There is a considerable prevalence of smoking habits in 
cardiovascular risk assessment studies.46–48 There is 
a considerable prevalence of smoking habits in cardiovas-
cular risk assessment studies. 46–48. The effect of tobacco 
within the organism occurs through nicotine. Its action 
prevents vasodilation of blood vessels and capillaries, 
remaining in a state of vasoconstriction, which increases 
blood pressure and compromises the arrival of oxygen 
molecules required in places such as the myocardium. In 
addition to cardiovascular implications generated from 
endothelial dysfunction, smoking can also influence the 
atherosclerosis process.49
Limitations of the Study
Due to the cross-sectional design of the study, it was 
impossible to obtain temporal information, such as in 
prospective studies. Further studies must be performed to 
obtain more accurate results regarding the association of 
these variables as these are still scarce in the literature, 
especially in regards to older adults.
Conclusion
The results of the present study provide convincing evidence 
that older adults with MS have high FRS values, and that the 
more MS components present, the higher the cardiovascular 
risk, which, in turn, may negatively affect the aging process 
of this population. The predictors of high cardiovascular risk 
are as follows: altered systolic blood pressure, male gender, 
diabetes mellitus presence, smoking habit, and alteration in 
HDL and LDL biochemical components.
It is worth remembering the background in which this 
study was conducted. The studied population resides in an 
underdevelopment region of the city that has a high popula-
tion density. The factors cited as predictive of cardiovascular 
risk are amenable to the identification and multi-professional 
intervention and may be used by primary health care teams 
for monitoring, treatment, and prevention. Establishing these 
therapeutic approaches for health promotion and prevention 
carries a high potential for improving the aging process of 
the population, therefore aiming for a better quality of life 
and healthy aging conditions.
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Further studies must investigate the chronic effects of MS 
on cardiovascular risk and their clinical impact, specifically 
in the older population of developing countries, where public 
healthcare systems are not prepared to meet their needs.
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